Do Not Stop Risperidone Abruptly—Switch to Another Antipsychotic Instead
When tardive dyskinesia (TD) develops in a patient on risperidone, you should NOT simply stop the medication now, unless the patient is in full remission and psychiatric stability is certain. Instead, attempt to either lower the dose or switch to another antipsychotic with a different receptor profile, most likely an atypical agent with lower D2 affinity such as clozapine or quetiapine 1.
Key Decision Points
Assess Current Psychiatric Status First
- If the patient is in full remission and there is strong reason to believe that any medication change will precipitate relapse, you may continue risperidone at the current dose despite TD 1
- If the patient is NOT in full remission (which is most cases), you must act to modify the antipsychotic regimen 1
Why Not Just Stop Now?
Abrupt discontinuation of risperidone carries significant risks:
Withdrawal dyskinesia may occur with sudden cessation, which can be difficult to distinguish from true TD. Withdrawal dyskinesias almost always resolve over time, whereas TD may persist even after discontinuation 1
Psychiatric relapse is a major concern—the underlying condition (likely schizophrenia or severe behavioral disorder) requires ongoing antipsychotic treatment 1
Abrupt withdrawal can paradoxically worsen TD—case reports document risperidone abruption-induced TD with symptoms appearing within 2 days of sudden discontinuation 2
Cholinergic rebound may occur when stopping medications with anticholinergic properties abruptly 3
Recommended Management Algorithm
Step 1: Confirm TD Diagnosis
- Use the Abnormal Involuntary Movement Scale (AIMS) to document baseline severity 1
- Rule out withdrawal dyskinesia (appears with cessation, typically resolves)
- Exclude other causes: acute dystonia, akathisia, parkinsonism, substance use, medical conditions
Step 2: Choose Your Strategy
Option A: Dose Reduction (if psychiatric symptoms allow)
- Gradually lower risperidone dose while monitoring both TD symptoms and psychiatric stability
- This may reduce TD severity while maintaining some symptom control
Option B: Switch to Lower-Risk Antipsychotic (preferred for most patients)
- Best choices: Clozapine or quetiapine—these have the lowest D2 affinity and lowest TD risk 4
- Switching method: Gradual cross-titration over several weeks, not abrupt cessation 3, 5
- Continue risperidone while slowly introducing the new agent
- Taper risperidone gradually as the new medication reaches therapeutic dose
- This approach minimizes both withdrawal dyskinesia and psychiatric destabilization
Step 3: Monitor During Transition
- Reassess AIMS every 2-4 weeks during the switch
- Watch for psychiatric symptom worsening
- TD may initially worsen during the switch but often improves over 8-12 weeks with appropriate management 6
Critical Caveats
The FDA label explicitly warns: "If signs and symptoms of tardive dyskinesia appear in a patient treated with RISPERDAL®, drug discontinuation should be considered. However, some patients may require treatment with RISPERDAL® despite the presence of the syndrome" 7. This reflects the reality that for many patients with serious mental illness, complete discontinuation is not clinically feasible.
Risperidone has higher TD risk than other atypicals due to its significant D2 antagonism, particularly at doses ≥2 mg/day 1. Your patient on 1.5 mg BID (3 mg/day total) is at the threshold where extrapyramidal effects become more likely.
Youth are particularly vulnerable—up to 50% may experience some form of tardive or withdrawal dyskinesia 1. If this is a pediatric patient, the urgency to modify treatment is even greater.
What About Supportive Treatments?
While switching antipsychotics, consider:
- Clonazepam has shown benefit in case reports for managing TD symptoms during transition 2
- VMAT inhibitors (deutetrabenazine, valbenazine) are first-line TD treatments but not yet widely available outside the US 4
- Avoid anticholinergics (benztropine, trihexyphenidyl) as they do not help TD and may worsen it 8
Bottom Line
Do not stop risperidone abruptly. The concern over TD should not outweigh the need for continued antipsychotic treatment in most patients 1. Execute a gradual cross-taper to a lower-risk agent like clozapine or quetiapine while monitoring both movement symptoms and psychiatric stability. Only in cases of full psychiatric remission with high confidence of sustained stability should you consider complete antipsychotic discontinuation.